This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Levine, T. B. Articles by Cohn, J. N. Search for Related Content PubMed PubMed Citation Articles by Levine, T. B. Articles by Cohn, J. N.

Circulation, Vol 69, 548-553, Copyright © 1984 by American Heart Association

ARTICLES

Hemodynamic and clinical response to enalapril, a long-acting converting-enzyme inhibitor, in patients with congestive heart failure

TB Levine, MT Olivari, V Garberg, SW Sharkey and JN Cohn

Enalapril, a new oral angiotensin converting-enzyme inhibitor, was administered to nine patients with severe congestive heart failure. Short-term hemodynamic response was noted within 2 hr and persisted for up to 24 hr. At peak effect mean arterial pressure fell from 83.4 +/- 10(SD) to 72.1 +/- 16.2 mm Hg (p less than .01), right atrial pressure from 13.6 +/- 6.0 to 10.4 +/- 7.5 mm Hg (p less than .01), pulmonary arterial pressure from 38.9 +/- 4.8 to 31.9 +/- 4.8 mm Hg (p less than .01), pulmonary capillary wedge pressure from 28.2 +/- 3.5 to 22.1 +/- 5.1 mm Hg (p less than .01), and total pulmonary resistance from 875 +/- 304 to 697 +/- 291 dynes-sec-cm-5 (p less than .05). Cardiac index was not changed, but there was a significant redistribution of regional blood flow with an increase of renal blood flow after enalapril. Plasma renin activity rose significantly from 6.2 to 28.6 ng/ml/hr, whereas plasma norepinephrine did not change after enalapril. Seven patients were treated with enalapril for 4 weeks. Five patients reported symptomatic improvement. Five of six patients tested had an increase in both exercise time (NS) and maximum oxygen consumption (NS). Repeat hemodynamic evaluation in six patients after long-term enalapril therapy showed a persistent effect with significant reductions in right atrial pressure from 13.8 +/- 7.2 to 7.1 +/- 4.7 mm Hg and in mean arterial pressure from 82.5 +/- 10.4 to 76.6 +/- 5.3 mm Hg and a significant increase in cardiac index from 2.1 +/- 0.5 to 2.5 +/- 0.5 l/min/m2 (all p less than .05).(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				A. C. Schoolwerth, D. A. Sica, B. J. Ballermann, and C. S. Wilcox Renal Considerations in Angiotensin Converting Enzyme Inhibitor Therapy: A Statement for Healthcare Professionals From the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association Circulation, October 16, 2001; 104(16): 1985 - 1991. [Full Text] [PDF]

				L. Baruch, I. Anand, I. S. Cohen, S. Ziesche, D. Judd, and J. N. Cohn Augmented Short- and Long-Term Hemodynamic and Hormonal Effects of an Angiotensin Receptor Blocker Added to Angiotensin Converting Enzyme Inhibitor Therapy in Patients With Heart Failure Circulation, May 25, 1999; 99(20): 2658 - 2664. [Abstract] [Full Text] [PDF]

				D E Newby, N E R Goodfield, A D Flapan, N A Boon, K A A Fox, and D J Webb Regulation of peripheral vascular tone in patients with heart failure: contribution of angiotensin II Heart, August 1, 1998; 80(2): 134 - 140. [Abstract] [Full Text]

				R. S. Stafford, D. Saglam, and D. Blumenthal National Patterns of Angiotensin-Converting Enzyme Inhibitor Use in Congestive Heart Failure Arch Intern Med, November 24, 1997; 157(21): 2460 - 2464. [Abstract] [PDF]

				D. Annane, E. Bellissant, E. Pussard, R. Asmar, F. Lacombe, E. Lanata, O. Madonna, M. Safar, J.-F. Giudicelli, and P. Gajdos Placebo-Controlled, Randomized, Double-Blind Study of Intravenous Enalaprilat Efficacy and Safety in Acute Cardiogenic Pulmonary Edema Circulation, September 15, 1996; 94(6): 1316 - 1324. [Abstract] [Full Text]

				J. N. Cohn The Management of Chronic Heart Failure N. Engl. J. Med., August 15, 1996; 335(7): 490 - 498. [Full Text] [PDF]

				I. Crozier, H. Ikram, N. Awan, J. Cleland, N. Stephen, K. Dickstein, M. Frey, J. Young, G. Klinger, L. Makris, et al. Losartan in Heart Failure : Hemodynamic Effects and Tolerability Circulation, February 1, 1995; 91(3): 691 - 697. [Abstract] [Full Text]

				D. L. Groden Vasodilator Therapy for Congestive Heart Failure: Lessons From Mortality Trials Arch Intern Med, February 22, 1993; 153(4): 445 - 454. [Abstract] [PDF]

				P. C. Deedwania Angiotensin-Converting Enzyme Inhibitors in Congestive Heart Failure Arch Intern Med, September 1, 1990; 150(9): 1798 - 1805. [Abstract] [PDF]